GSK has released new preliminary data showing that its respiratory syncytial virus (RSV) vaccine Arexvy met primary endpoints in a Phase III trial in adults aged 50 to 59 years.
The study also included adults who are at an increased RSV lower respiratory tract disease (LRTD) due to certain underlying medical conditions.
While the company did not share detailed results, it revealed that the Arexvy elicited an immune response in subjects with increased risk for RSV disease due to certain medical conditions.
The immune response was non-inferior to what was observed in the approved patient population of adults aged 60 and above, meeting the trial’s co-primary endpoint. This was also observed in the broader patient population of the trial.
Arexvy’s safety and reactogenicity data were consistent with the already established safety profile in the approved patient population. Pain was the most common local adverse event, with patients also reporting systematic adverse events such as fatigue and headache.
See Also:
According to GSK, it is on track to be the first company to submit data on this patient population to regulators. GSK anticipates hearing back from regulatory agencies on their decision for potential label expansion in 2024.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe results were presented at the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) meeting on 25 October 2023. GSK plans to present full data from the trial at an upcoming medical conference and submit it for peer-reviewed publication.
Arexvy was first approved by the US Food and Drug Administration (FDA) for adults aged 60 and above in May. Other regulatory agencies followed suit, and the vaccine is currently approved in Europe, Japan, the UK, and Canada. In June, the US Centers for Disease Control and Prevention (CDC) also backed GSK’s Arexvy, alongside Pfizer’s Abrysvo.
RSV landscape
RSV is a common and contagious virus that usually causes mild symptoms but can lead to severe respiratory illness.
In July, Moderna announced global regulatory submissions for its RSV vaccine MRNA-1345. The following month, a US-based biotech Meissa Vaccines reported positive data from its Phase I trial investigating intranasal vaccine MV-012-968 in a paediatric population.
However, not everyone is succeeding in the RSV space. In July, Bavarian Nordic shelved its MVA-BN RSV after the vaccine candidate failed to meet the co-primary endpoint of severe LRTD in a Phase III trial.
According to GlobalData’s Clinical Trial Database, there are 45 ongoing or planned Phase I-III trials investigating RSV vaccines. The majority of trials are in Phase I (35.6%), followed by Phase III trials (31.1%). GlobalData is the parent company of Pharmaceutical Technology.
